Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.49 |
| ▸ | RAMP3 | O60896 | 8/20 | 0.47 |
| ▸ | CALCR | P30988 | 8/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | KDM5A | P29375 | 1/20 | 0.45 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.45 |
| ▸ | GLP1R | P43220 | 6/20 | 0.45 |
| ▸ | GCGR | P47871 | 5/20 | 0.45 |
| ▸ | GIPR | P48546 | 5/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.44 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10066201 | 0.86 | PRSS1 (0.49) | APLNRRAMP3CALCRF2PLG | |
| SCHEMBL10065813 | 0.85 | PRSS1 (0.47) | APLNRF2PLGPRSS1PRSS2 | |
| SCHEMBL10065714 | 0.79 | PRSS1 (0.50) | RAMP3CALCRF2PLGPRSS1 | |
| SCHEMBL12984646 | 0.76 | RAMP3 (0.63) | APLNRRAMP3CALCRPIN1 | |
| SCHEMBL24601727 | 0.76 | GLP1R (0.60) | GLP1RGCGRGIPR | |
| SCHEMBL26346380 | 0.76 | GLP1R (0.60) | GLP1RGCGRGIPR | |
| SCHEMBL22550671 | 0.75 | RAMP3 (0.53) | RAMP3CALCRKDM1AMAOBKDM5A | |
| SCHEMBL24601539 | 0.75 | F2 (0.50) | GLP1RGCGRGIPRF2PLG | |
| SCHEMBL10066227 | 0.75 | CAPN1 (0.46) | CALCR | |
| SCHEMBL12985549 | 0.74 | CAPN1 (0.46) | CALCRF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100316563-A1 | Method For The Preparation Of New Oligoclonal Antibodies | BRACCO IMAGING S.P.A. (IT) | 2010-12-16 | — | — | US | disclosed |
| US-20100316563-A1 | Method For The Preparation Of New Oligoclonal Antibodies | BRACCO IMAGING S.P.A. (IT) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316563-A1 | Method For The Preparation Of New Oligoclonal Antibodies | APOB, APOL1, FCGR3B | APLNR 443/4885RAMP3 3589/4885CALCR 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.